Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations.

Fiskus W, Mill CP, Piel J, Collins M, Hentemann M, Cuglievan B, Birdwell CE, Das K, Hou H, Davis JA, Jain A, Malovannaya A, Kadia TM, Daver N, Sasaki K, Takahashi K, Hammond D, Reville PK, Flores LB, Loghavi S, Su X, DiNardo CD, Bhalla KN

Open source

DOI: 10.1038/s41408-025-01251-7
Published: 2025 Mar 15
Container: Blood cancer journal
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41408-025-01251-7,
  title = {Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations.},
  author = {Fiskus W and Mill CP and Piel J and Collins M and Hentemann M and Cuglievan B and Birdwell CE and Das K and Hou H and Davis JA and Jain A and Malovannaya A and Kadia TM and Daver N and Sasaki K and Takahashi K and Hammond D and Reville PK and Flores LB and Loghavi S and Su X and DiNardo CD and Bhalla KN},
  year = {2025},
  journal = {Blood cancer journal},
  doi = {10.1038/s41408-025-01251-7},
  url = {https://doi.org/10.1038/s41408-025-01251-7}
}

RIS

TY  - JOUR
TI  - Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations.
AU  - Fiskus W
AU  - Mill CP
AU  - Piel J
AU  - Collins M
AU  - Hentemann M
AU  - Cuglievan B
AU  - Birdwell CE
AU  - Das K
AU  - Hou H
AU  - Davis JA
AU  - Jain A
AU  - Malovannaya A
AU  - Kadia TM
AU  - Daver N
AU  - Sasaki K
AU  - Takahashi K
AU  - Hammond D
AU  - Reville PK
AU  - Flores LB
AU  - Loghavi S
AU  - Su X
AU  - DiNardo CD
AU  - Bhalla KN
PY  - 2025
JO  - Blood cancer journal
DO  - 10.1038/s41408-025-01251-7
UR  - https://doi.org/10.1038/s41408-025-01251-7
ER  -

APA

W, F., CP, M., J, P., M, C., M, H., B, C., CE, B., K, D., H, H., JA, D., A, J., A, M., TM, K., N, D., K, S., K, T., D, H., PK, R., LB, F., S, L., X, S., CD, D., & KN, B. (2025). Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations.. Blood cancer journal. https://doi.org/10.1038/s41408-025-01251-7

Source records

pubmed · retrieved 2026-09-26T08:37:12.925Z
europe-pmc · retrieved 2026-09-26T08:37:12.948Z
doaj · retrieved 2026-09-26T08:37:13.033Z